3.275
price up icon8.80%   0.265
after-market Dopo l'orario di chiusura: 3.23 -0.045 -1.37%
loading
Precedente Chiudi:
$3.01
Aprire:
$3.11
Volume 24 ore:
33,706
Relative Volume:
1.14
Capitalizzazione di mercato:
$93.73M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-1.06%
1M Prestazione:
+26.45%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
Value
$3.03
$3.29
Intervallo di 1 settimana:
Value
$3.01
$3.57
Portata 52W:
Value
$2.33
$3.598

Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile

Name
Nome
Insight Molecular Diagnostics Inc
Name
Telefono
949-409-7600
Name
Indirizzo
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Name
Dipendente
49
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
IMDX's Discussions on Twitter

Confronta IMDX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Diagnostics & Research icon
IMDX
Insight Molecular Diagnostics Inc
3.275 86.15M 0 0 0 0.00
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
468.00 177.38B 43.21B 6.58B 6.17B 17.29
Diagnostics & Research icon
DHR
Danaher Corp
185.91 135.85B 24.01B 3.41B 4.86B 4.70
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
627.17 51.87B 4.04B 985.66M 774.34M 12.01
Diagnostics & Research icon
A
Agilent Technologies Inc
124.38 35.70B 6.79B 1.22B 1.09B 4.26
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
181.24 31.70B 15.70B 1.24B 2.01B 6.91

Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-28 Iniziato Lake Street Buy
2022-05-24 Downgrade Stephens Overweight → Equal-Weight
2022-03-14 Downgrade KeyBanc Capital Markets Overweight → Sector Weight
2022-01-07 Iniziato Stephens Overweight
2022-01-06 Ripresa Piper Sandler Overweight
2021-03-17 Ripresa Needham Buy
2021-01-07 Aggiornamento The Benchmark Company Speculative Buy → Buy
2020-12-16 Aggiornamento Piper Sandler Neutral → Overweight
2020-11-30 Iniziato BTIG Research Buy
2020-11-10 Iniziato KeyBanc Capital Markets Overweight
2020-07-30 Reiterato The Benchmark Company Speculative Buy
2020-07-01 Downgrade Piper Sandler Overweight → Neutral
2020-06-30 Downgrade Chardan Capital Markets Buy → Neutral
2020-06-02 Iniziato Needham Buy
2019-02-13 Iniziato Piper Jaffray Overweight
2019-01-29 Aggiornamento Janney Neutral → Buy
2018-12-19 Ripresa Lake Street Buy
Mostra tutto

Insight Molecular Diagnostics Inc Borsa (IMDX) Ultime notizie

pulisher
09:43 AM

HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer? - TradingView

09:43 AM
pulisher
07:47 AM

Insight Molecular Diagnostics (IMDX) Highlights GraftAssur at In - GuruFocus

07:47 AM
pulisher
07:07 AM

Insight Molecular Diagnostics to Showcase Leadership in - GlobeNewswire

07:07 AM
pulisher
Sep 19, 2025

Insight Molecular Diagnostics Approves Executive Salary Increases - TipRanks

Sep 19, 2025
pulisher
Sep 16, 2025

Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East - Quantisnow

Sep 16, 2025
pulisher
Sep 15, 2025

North America In Vitro Diagnostics (IVD) Market Insights and Future Outlook - openPR.com

Sep 15, 2025
pulisher
Sep 13, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Sep 13, 2025
pulisher
Sep 09, 2025

Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail

Sep 09, 2025
pulisher
Sep 08, 2025

iMDx launches 5,000-patient registry to study transplant rejection test - Investing.com

Sep 08, 2025
pulisher
Sep 08, 2025

iMDx launches 5,000-patient registry to study transplant rejection test By Investing.com - Investing.com Nigeria

Sep 08, 2025
pulisher
Sep 08, 2025

Insight Molecular Diagnostics (IMDX) Launches New Patient Regist - GuruFocus

Sep 08, 2025
pulisher
Sep 08, 2025

IMDX Advances GraftAssureDx Clinical Trial for Transplant Rejection Test - GuruFocus

Sep 08, 2025
pulisher
Sep 08, 2025

Insight Molecular Diagnostics Inc. Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants - MarketScreener

Sep 08, 2025
pulisher
Sep 08, 2025

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants - GlobeNewswire

Sep 08, 2025
pulisher
Sep 08, 2025

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database - The Manila Times

Sep 08, 2025
pulisher
Sep 05, 2025

Insight Molecular Diagnostics Inc. shares rise 1.62% premarket after Myriad Genetics announces positive MRD test results. - AInvest

Sep 05, 2025
pulisher
Sep 05, 2025

Molecular Diagnostics Market: Applications, Growth, and Future Trends - newstrail.com

Sep 05, 2025
pulisher
Sep 02, 2025

Insight Molecular Diagnostics Inc. shares rise 1.78% intraday after QIAGEN gains U.S. clearance for higher-throughput syndromic testing system. - AInvest

Sep 02, 2025
pulisher
Aug 26, 2025

iMDx to Participate in NYC Investment Conferences September 811 - GlobeNewswire

Aug 26, 2025
pulisher
Aug 26, 2025

iMDx Announces Participation in NYC Investment Conferences - AInvest

Aug 26, 2025
pulisher
Aug 26, 2025

Molecular Diagnostics Leader iMDx Announces Double-Header NYC Investor Conference Schedule for September - Stock Titan

Aug 26, 2025
pulisher
Aug 25, 2025

iMDx CFO Andrea James discusses democratizing molecular diagnostics in podcast episode. - AInvest

Aug 25, 2025
pulisher
Aug 25, 2025

IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics - MarketScreener

Aug 25, 2025
pulisher
Aug 23, 2025

HIV Diagnostics Market Size, Share & Forecast, 2025–2034 - Global Market Insights Inc.

Aug 23, 2025
pulisher
Aug 20, 2025

Global Minimal Residual Disease Testing Market Gearing Up for Outstanding Expansion at a CAGR of ~11% by 2032 | DelveInsight - PR Newswire UK

Aug 20, 2025
pulisher
Aug 19, 2025

Insight Molecular Diagnostics: Pioneering the Next Generation of Transplant Rejection Testing and FDA Readiness - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Veterinary Molecular Diagnostics Market on Track for Massive Expansion by 2035, Forecasts Reveal. - newstrail.com

Aug 19, 2025
pulisher
Aug 19, 2025

Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Insight Molecular Diagnostics (IMDX) - The Globe and Mail

Aug 19, 2025
pulisher
Aug 19, 2025

Sepsis Diagnostics Market Poised for Remarkable Expansion by 2035, Reveals Prophecy Market Insights Study - newstrail.com

Aug 19, 2025
pulisher
Aug 18, 2025

Insight Molecular Diagnostics Inc. shares rise 12.92% intraday after Myriad Genetics appoints new CFO. - AInvest

Aug 18, 2025
pulisher
Aug 18, 2025

Molecular Diagnostics Market Evolving Rapidly from 2025 to 2032 | F. Hoffmann-La Roche Ltd, Illumina, Inc. - openPR.com

Aug 18, 2025
pulisher
Aug 18, 2025

Insight Molecular: Needham Reiterates Buy Rating with $4.25 PT - AInvest

Aug 18, 2025
pulisher
Aug 18, 2025

Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛

Aug 18, 2025
pulisher
Aug 15, 2025

Insight Molecular Diagnostics: Paving the Next Frontier in Transplant Rejection Testing with FDA-Ready Innovation - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

IMDX’s GraftAssureDx Study: A Game-Changer in Kidney Transplant Monitoring? - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

Insight Molecular Diagnostics Inc. shares rise 1.21% intraday after Caris Life Sciences validates MI Cancer Seek® assay. - AInvest

Aug 15, 2025
pulisher
Aug 14, 2025

Insight Molecular Diagnostics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

Aug 14, 2025
pulisher
Aug 13, 2025

Insight Molecular Diagnostics : With Q&A (insight molecular diagnostics inc imdx us q2 2025 earnings call 11 august 2025 5 00 pm et) - MarketScreener

Aug 13, 2025
pulisher
Aug 13, 2025

Lake Street Sticks to Their Buy Rating for Insight Molecular Diagnostics (IMDX) - The Globe and Mail

Aug 13, 2025
pulisher
Aug 13, 2025

In Vitro Diagnostics Market to Hit USD 197.06 Billion by 2032, Driven by a Surge in Chronic and Infectious Disease Burden | Coherent Market Insights - BioSpace

Aug 13, 2025
pulisher
Aug 12, 2025

Insight Molecular Diagnostics Inc. shares fall 1.53% intraday after reporting a Q2 loss of $9.7 million. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Insight Molecular Diagnostics Inc (IMDX) Q2 2025 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance

Aug 12, 2025
pulisher
Aug 12, 2025

Needham reiterates Buy rating on Insight Molecular Diagnostics stock By Investing.com - Investing.com Nigeria

Aug 12, 2025
pulisher
Aug 12, 2025

Needham reiterates Buy rating on Insight Molecular Diagnostics stock - Investing.com India

Aug 12, 2025
pulisher
Aug 12, 2025

Insight Molecular Diagnostics: Promising Future with GraftAssureIQ and Strategic Expansion - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

Insight Molecular Diagnostics: Q2 Earnings Snapshot - Connecticut Post

Aug 12, 2025
pulisher
Aug 12, 2025

Insight Molecular Diagnostics Reports Q2 2025 Progress - TipRanks

Aug 12, 2025
pulisher
Aug 11, 2025

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch - Santé log

Aug 11, 2025
pulisher
Aug 11, 2025

Earnings call transcript: Insight Molecular Diagnostics Q2 2025 reveals strategic advancements - Investing.com Canada

Aug 11, 2025
pulisher
Aug 11, 2025

Insight Molecular Diagnostics Reports Q2 Loss of $9.7 Million - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx L - GuruFocus

Aug 11, 2025

Insight Molecular Diagnostics Inc Azioni (IMDX) Dati Finanziari

Non sono disponibili dati finanziari per Insight Molecular Diagnostics Inc (IMDX). Controlla altri titoli per ulteriori informazioni.

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
diagnostics_research WAT
$292.65
price down icon 2.20%
diagnostics_research DGX
$186.82
price down icon 0.08%
$163.91
price down icon 5.16%
diagnostics_research LH
$279.35
price down icon 0.21%
diagnostics_research MTD
$1,242.28
price down icon 1.17%
diagnostics_research IQV
$181.24
price down icon 2.79%
Capitalizzazione:     |  Volume (24 ore):